DexCom Inc. (DXCM) exhibits 60.1% gross margins and 21.6% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 25.2x enterprise multiple and 7.2% implied options volatility.
Sustained 60.1% gross profitability converts into 19.6% operating margin and 21.6% ROIC, outpacing sector cost of capital.
ROIC: 21.6% // GM: 60.1%YoY revenue trajectory of +15.6% paired with 3.57% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +15.6% // FCF YLD: 3.57%Altman Z-Score of 7.14 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 7.14 // F-SCORE: 9/9Trading at 36.1x trailing P/E (30.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 36.1x // EV/EBITDA: 25.2xOptions market prices a ±7.2% implied move with a 0.86 put/call ratio around $78.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.86Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 17.9% net margins.
NET MARGIN: 17.9% // D/E: 0.55x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for DXCM & activate live FRED threshold breach alerts.